Carcinoid syndrome, a paraneoplastic condition linked with the release of multiple humoral
factors, affects around 30-40% of patients with well-differentiated neuroendocrine tumours …

Approximately 30-40% of patients with well-differentiated neuroendocrine tumors present
with carcinoid syndrome, which is a paraneoplastic syndrome associated with the secretion …

This review reports on the currently available medical treatment options for the control of
symptoms due to carcinoid syndrome in patients with neuroendocrine tumors. The efficacy …

Opinion statement Carcinoid syndrome (CS) is a complex disorder caused by functional
neuroendocrine tumors (NETs). This debilitating disease is characterized by hyper-secretion …

Background: Carcinoid syndrome symptoms significantly reduce quality of life in patients
with neuroendocrine tumors. Evidence supporting the use of somatostatin analogues in …

Carcinoid tumors originate from the neuroendocrine cells throughout the body and are
capable of producing various peptides. Their clinical course is often indolent but can also be …

Carcinoid syndrome (CSy) is a constellation of symptoms that may commonly present in
patients with well differentiated neuroendocrine tumors (NETs), with somatostatin analogs …

There have been numerous advances in all aspects of the carcinoid-syndrome, which is the
most common functional syndrome neuroendocrine tumors produce. These advances are …

Carcinoid syndrome (CS) is a debilitating disease caused by functional neuroendocrine
tumors. Several treatment options are available to alleviate the hormonal symptoms, but …

“Carcinoids” are mostly slow-growing neuroendocrine neoplasms (NENs) with low
proliferative activity. A wide range of therapeutic options with variable efficacy exist …